FindTrial
Sign In

A phase II study of TAK-442 in patients with arterial thrombosis

A phase II study of TAK-442 in patients with arterial thrombosis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220834
Enrollment
Unknown
Registered
2009-09-01
Start date
2009-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial thrombosis

Interventions

investigational material(s) Generic name etc : TAK-442 INN of investigational material : Therapeutic category code : 333 Anticoagulants Dosage and Administration for Investigational material : Oral

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 30-80 years (inclusive) with onset of arterial thrombosis Others

Exclusion criteria

Exclusion criteria: 1. Known hemorrhagic/coagulation disorder 2. Past or current history of intracranial hemorrhage. 3. Patients with a condition indicated for long-term anticoagulant therapy 4. Severe renal dysfunction or liver disorder Others

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026